<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706692</url>
  </required_header>
  <id_info>
    <org_study_id>IMM 10-0138; P21007224R</org_study_id>
    <secondary_id>CNTO1275PSO4028; AG110401-IIR</secondary_id>
    <nct_id>NCT01706692</nct_id>
  </id_info>
  <brief_title>Swiss Dermatology Network of Targeted Therapies (SDNTT)</brief_title>
  <acronym>SDNTT</acronym>
  <official_title>Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Dermatology Network for Targeted Therapies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Dermatology Network for Targeted Therapies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term course of patients with psoriasis and
      psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric
      acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A
      patient will be included at first initiation of the treatment and will remain in the registry
      for 5 years, regardless of subsequent therapy.

      The registry will also evaluate safety clinical outcomes and health related quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) in Switzerland
      is largely performed with systemic therapies. This includes conventional systemic therapy
      such as fumaric acids, methotrexate, cyclosporin A, retinoids, systemic PUVA, Acitretin and
      biological treatments such as etanercept, infliximab, adalimumab and within a
      pre-registration program ustekinumab. While short- and middle-term efficacy of most systemic
      treatments has been shown in clinical studies (and is incorporated in international
      guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under
      real-world conditions is still missing. SDNTT, the Swiss registry on the treatment of
      moderate to severe Pso and PsA documents the long-term course of patients being administered
      a defined biologic or conventional systemic drug. Following outcomes are observed:
      Effectiveness on the long-term, of combined/alternating treatments and under comorbidity
      conditions; patient-defined benefits and quality of life, maintenance dosages, prediction of
      response and safety.

      The study evaluates the long-term course of patients with Pso and PsA in systemic treatments.
      A patient will be included at first initiation of the treatment and will remain in the
      registry for 5 years, regardless of subsequent therapy. Nationwide, initially 35 (long-term
      approx. 50-80) dermatologic practices and hospital ambulances with expertise in systemic and
      biologic treatment will consecutively enroll patients. Follow-ups will be every 3 months,
      comprising patient and treatment characteristics, clinical parameters, patient-defined
      benefit, quality of life and adverse events. Standardized questionnaires will be addressed to
      the patient and to the dermatologist 12 times at the dermatologic centres. In interim
      intervals, patients are directly contacted another 9 times by mail.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <description>To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>every 6 months for 5 years</time_frame>
    <description>To evaluate health related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse and serious adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <description>Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <description>Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <description>Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <description>Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fumaric acids</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other anti-psoriatic systemic treatments</arm_group_label>
    <description>e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Ustekinumab</arm_group_label>
    <other_name>Stelara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaric acids</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Fumaric acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other anti-psoriatic systemic treatments</intervention_name>
    <description>all dosages, frequencies and durations prescribed</description>
    <arm_group_label>Other anti-psoriatic systemic treatments</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with psoriasis or psoriatic-arthritis meeting the inclusion criteria and not
        meeting the exclusion criteria will be eligible to participate in this registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a
             dermatologist,

          -  age ≥ 18,

          -  Being administered a specific biologic/conventional systemic drug for the first time

          -  Sufficient language skills (German, French, Italian and English) for the informed
             consent to participate

          -  Informed consent to participate

        Exclusion Criteria:

          -  Lack of informed consent

          -  Patients being participants of clinical trials at the day of registration to the
             registry (if a patient is included into a clinical trial during the registry
             follow-ups, the patient data will be recorded, but analyzed separately)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars French, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Society of Dermatology and Venereology (SSDV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Itin, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Society of Dermatology and Venereology (SSDV)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarau Cantonal Hospital</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Streit, Dr. med.</last_name>
      <phone>062 838 68 38</phone>
      <email>markus.streit@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Marcus Streit, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Itin, Prof.</last_name>
      <email>pitin@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Peter Itin, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital - Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Borradori, Prof. Dr.</last_name>
      <phone>031 632 2111</phone>
      <email>Luca.Borradori@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Luca Borradori, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Gilliet, Prof.</last_name>
      <email>michel.gilliet@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Curdin Conrad, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Gallen Cantonal Hospital</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Bühler, Dr. med.</last_name>
      <email>damian.buehler@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Mark Anliker, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zurich University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Navarini, Dr.</last_name>
      <email>alexander.navarini@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Lars French, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.psobest.de/</url>
    <description>German registry PsoBest</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Acitretin</keyword>
  <keyword>Cyclosporine A</keyword>
  <keyword>Systemic PUVA</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>Fumaric acids</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Skin disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

